CTOs on the Move

Operon Biotechnologies

www.operon.com

 
Operon Biotechnologies, Inc is a Huntsville, AL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million
  • www.operon.com
  • 2705 Artie St SW Ste 27
    Huntsville, AL USA 35805
  • Phone: 800.688.2248

Executives

Name Title Contact Details

Similar Companies

OLIVIAGroup

OLIVIAGroup is a West Chester, PA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

New Century Pharmaceuticals

New Century Pharmaceuticals is a Huntsville, AL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

St. Mary's Janesville Hospital

St. Mary's Janesville Hospital is a Janesville, WI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Voluntis

At the forefront of the medical and digital revolutions, Voluntis is a pioneer of digital therapeutics. We design prescription applications that embed medical intelligence in the smartphones of people suffering from chronic and rare diseases. By using our software, patients leverage their health data to simplify their medical care. Treatment is personalized, doctors and patients are connected to coordinate care and real-world outcomes are improved. Harnessing its proprietary technology, Voluntis has developed digital solutions for diabetes, respiratory diseases, cancer, anticoagulation and hemophilia. Whether in our French or US offices, we are always on the look out for talent that is passionate about digital technologies and changing patients`​ lives.

Quadrant Biosciences

Quadrant Biosciences is an epigenetic diagnostics company with a focus on the early detection of neurological disorders and other large-scale health issues. Revolutionary advancements in the early detection of autism spectrum disorder, Parkinson’s disease, and mTBI, through the application of the Clarifi® epigenetic diagnostic platform, could have a significant impact on the way clinicians approach the diagnosis and treatment of these serious conditions. In March 2020, we made the decision to pivot and allocate some of our resources to directly address the pandemic. By leveraging our expertise in RNA analysis, we have been able to be part of three exciting COVID-19 projects to aid in the detection of COVID-19 in individuals and communities across the U.S.